טבע תדווח על תגמול בכירים החל מהדו"ח השנתי לשנת 2013

החברה מודיעה כי יישבה את התביעה הייצוגית בנידון

18 יונ 2013 | זמן קריאה ממוצע: 1 דקות

ירושלים, 19 ביוני, 2013 – טבע תעשיות פרמצבטיות בע"מ (NYSE: TEVA) הודיעה היום כי בהתאם למאמציה להנחיל שקיפות מרבית לבעלי המניות שלה, בכוונתה לדווח על תגמול מנהליה הבכירים והדירקטורים שלה על בסיס אישי, החל בדו"ח השנתי של החברה לשנת 2013 הצפוי להתפרסם בתחילת 2014.

נוכח החלטתה זו של טבע, יישבה טבע את התביעה הייצוגית שהוגשה נגדה בישראל לפני מספר חודשים בנוגע לאופן דיווח תגמול הבכירים של החברה בדוחותיה השנתיים.

הסכם הפשרה כולל תשלום שכ"ט עורכי דין והוצאות אחרות על סך 1.1 מיליון דולר ארה"ב ועוד תגמול על סך 200,000 דולר ארה"ב לתובעים.

הסכם הפשרה כפוף לאישורו של בית המשפט המחוזי בתל אביב.

Teva’s Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995:

January 1st 0001 | Reading time: 2 Min

This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management’s current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialize additional pharmaceutical products, competition for our innovative products, especially Copaxone® (including competition from innovative orally-administered alternatives, as well as from potential purported generic equivalents), competition for our generic products (including from other pharmaceutical companies and as a result of increased governmental pricing pressures), competition for our specialty pharmaceutical businesses, our ability to achieve expected results through our innovative R&D efforts, the effectiveness of our patents and other protections for innovative products, decreasing opportunities to obtain U.S. market exclusivity for significant new generic products, our ability to identify, consummate and successfully integrate acquisitions, the effects of increased leverage as a result of recent acquisitions, the extent to which any manufacturing or quality control problems damage our reputation for high quality production and require costly remediation, our potential exposure to product liability claims to the extent not covered by insurance, increased government scrutiny in both the U.S. and Europe of our agreements with brand companies, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, our exposure to currency fluctuations and restrictions as well as credit risks, the effects of reforms in healthcare regulation and pharmaceutical pricing and reimbursement, any failures to comply with complex Medicare and Medicaid reporting and payment obligations, governmental investigations into sales and marketing practices (particularly for our specialty pharmaceutical products), uncertainties surrounding the legislative and regulatory pathways for the registration and approval of biotechnology-based products, adverse effects of political or economical instability, corruption, major hostilities or acts of terrorism on our significant worldwide operations, interruptions in our supply chain or problems with our information technology systems that adversely affect our complex manufacturing processes, any failure to retain key personnel or to attract additional executive and managerial talent, the impact of continuing consolidation of our distributors and customers, variations in patent laws that may adversely affect our ability to manufacture our products in the most efficient manner, potentially significant impairments of intangible assets and goodwill, potential increases in tax liabilities, the termination or expiration of governmental programs or tax benefits, environmental risks and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2012 and in our other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

 

כתבות נוספות בנושא